Long-term functional outcome after laryngeal cancer treatment.


Journal

Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111

Informations de publication

Date de publication:
11 Jun 2019
Historique:
received: 13 03 2019
accepted: 16 05 2019
entrez: 13 6 2019
pubmed: 13 6 2019
medline: 18 12 2019
Statut: epublish

Résumé

The functional outcome after the treatment of laryngeal cancer is tightly related to the quality of life of affected patients. The aim of this study is to describe the long-term morbidity and functional outcomes associated with the different treatment modalities for laryngeal cancer. Retrospective chart review of 477 patients undergoing curatively intended treatment for laryngeal cancer at our tertiary referral center from 2001 to 2014: Details on patient and disease characteristics, diagnostics and treatment related functional outcomes were analyzed. With a median follow-up of 51 months, the crude rate of functional larynx preservation was 74.6%. Radiotherapy +/- chemotherapy was the dominant treatment modality (n = 359-75.3%), whereas 24.7% (n = 118) underwent primary surgery, with 58.5% (69) receiving adjuvant treatment. The 5-year laryngectomy-free survival was 57% (95% CI, 48-66%) after surgery vs. 69% (95% CI, 64-75%) after chemoradiotherapy (p < 0.01). In stage III-IVB, these rates were 26% (95% CI, 16-39%) vs. 47% (95% CI, 36-59%), respectively (p < 0.01). Aspiration occurred in 7%, tracheostomy was necessary in 19.8% and feeding tube placement in 25.4%. Feeding tube and tracheostomy necessity was higher in the initially surgically treated group. Primary surgery (HR: 1.67, 95% CI: 1.19-2.32; p < 0.01), stage III-IVB (HR: 4.07, 95% CI: 2.97-5.60; p < 0.01) and tumor recurrence (HR: 3.83, 95% CI: 2.79-5.28; p < 0.01) remained as adverse factors for laryngectomy-free survival. Preserving the laryngeal function after cancer treatment is challenging. Advanced tumor stages, primary surgery and recurrence are related to a poor functional outcome. Therefore, the criteria for initial decision-making needs to be further refined.

Sections du résumé

BACKGROUND BACKGROUND
The functional outcome after the treatment of laryngeal cancer is tightly related to the quality of life of affected patients. The aim of this study is to describe the long-term morbidity and functional outcomes associated with the different treatment modalities for laryngeal cancer.
METHODS METHODS
Retrospective chart review of 477 patients undergoing curatively intended treatment for laryngeal cancer at our tertiary referral center from 2001 to 2014: Details on patient and disease characteristics, diagnostics and treatment related functional outcomes were analyzed.
RESULTS RESULTS
With a median follow-up of 51 months, the crude rate of functional larynx preservation was 74.6%. Radiotherapy +/- chemotherapy was the dominant treatment modality (n = 359-75.3%), whereas 24.7% (n = 118) underwent primary surgery, with 58.5% (69) receiving adjuvant treatment. The 5-year laryngectomy-free survival was 57% (95% CI, 48-66%) after surgery vs. 69% (95% CI, 64-75%) after chemoradiotherapy (p < 0.01). In stage III-IVB, these rates were 26% (95% CI, 16-39%) vs. 47% (95% CI, 36-59%), respectively (p < 0.01). Aspiration occurred in 7%, tracheostomy was necessary in 19.8% and feeding tube placement in 25.4%. Feeding tube and tracheostomy necessity was higher in the initially surgically treated group. Primary surgery (HR: 1.67, 95% CI: 1.19-2.32; p < 0.01), stage III-IVB (HR: 4.07, 95% CI: 2.97-5.60; p < 0.01) and tumor recurrence (HR: 3.83, 95% CI: 2.79-5.28; p < 0.01) remained as adverse factors for laryngectomy-free survival.
CONCLUSIONS CONCLUSIONS
Preserving the laryngeal function after cancer treatment is challenging. Advanced tumor stages, primary surgery and recurrence are related to a poor functional outcome. Therefore, the criteria for initial decision-making needs to be further refined.

Identifiants

pubmed: 31186027
doi: 10.1186/s13014-019-1299-8
pii: 10.1186/s13014-019-1299-8
pmc: PMC6558792
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101

Références

Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):23-8
pubmed: 12007937
Otolaryngol Head Neck Surg. 2002 Jul;127(1):43-7
pubmed: 12161729
Arch Otolaryngol Head Neck Surg. 2003 Jan;129(1):44-9
pubmed: 12525193
Radiother Oncol. 2003 Mar;66(3):253-62
pubmed: 12742264
Ann Otol Rhinol Laryngol. 2007 Jan;116(1):19-23
pubmed: 17305273
Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):410-5
pubmed: 18635320
J Natl Cancer Inst. 2009 Feb 4;101(3):142-52
pubmed: 19176454
Head Neck. 2010 Feb;32(2):139-47
pubmed: 19536855
N Engl J Med. 1991 Jun 13;324(24):1685-90
pubmed: 2034244
Dysphagia. 2011 Dec;26(4):399-406
pubmed: 21344191
Head Neck. 2012 Feb;34(2):254-9
pubmed: 21384461
Curr Oncol Rep. 2012 Apr;14(2):158-65
pubmed: 22249533
Otolaryngol Head Neck Surg. 2013 Jan;148(1):64-8
pubmed: 22951428
Ann Otol Rhinol Laryngol. 2012 Sep;121(9):570-5
pubmed: 23012894
J Clin Oncol. 2013 Mar 1;31(7):845-52
pubmed: 23182993
Head Neck. 2014 Nov;36(11):1604-10
pubmed: 24115115
Head Neck. 2014 Nov;36(11):1628-33
pubmed: 24115178
Eur Ann Otorhinolaryngol Head Neck Dis. 2014 Apr;131(2):93-7
pubmed: 24529928
Laryngoscope. 2014 Dec;124(12):2707-13
pubmed: 24577936
Laryngoscope. 2015 Sep;125(9):2143-56
pubmed: 26013745
Laryngoscope. 2016 Feb;126(2):385-91
pubmed: 26344401
Eur Arch Otorhinolaryngol. 2016 Nov;273(11):3943-3949
pubmed: 27107580
Radiother Oncol. 2018 Jan;126(1):56-67
pubmed: 28943045
J Oncol Pract. 2018 Feb;14(2):123-128
pubmed: 29172913
J Clin Oncol. 2018 May 1;36(13):1376-1377
pubmed: 29558275
Head Neck. 2018 Nov;40(11):2469-2475
pubmed: 30307670
N Engl J Med. 1981 Oct 22;305(17):982-7
pubmed: 7278922
Arch Otolaryngol Head Neck Surg. 1995 Feb;121(2):162-5
pubmed: 7840923
Ann Otol Rhinol Laryngol Suppl. 1998 May;172:1-27
pubmed: 9597955
Arch Otolaryngol Head Neck Surg. 1998 Sep;124(9):964-71
pubmed: 9738804

Auteurs

Lukas Anschuetz (L)

Department of Otorhinolaryngology, Head & Neck Surgery, Inselspital, Bern University Hospital, University of Bern, 3010, Bern, Switzerland.

Mohamed Shelan (M)

Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, 3010, Bern, Switzerland.

Marco Dematté (M)

Department of Otorhinolaryngology, Head & Neck Surgery, Inselspital, Bern University Hospital, University of Bern, 3010, Bern, Switzerland.
Department of Otorhinolaryngology, Head & Neck Surgery, Head and Neck and Sensory Organs Department, Sant'Orsola-Malpighi Hospital, University of Bologna, 40138, Bologna, Italy.

Adrian D Schubert (AD)

Department of Otorhinolaryngology, Head & Neck Surgery, Inselspital, Bern University Hospital, University of Bern, 3010, Bern, Switzerland.

Roland Giger (R)

Department of Otorhinolaryngology, Head & Neck Surgery, Inselspital, Bern University Hospital, University of Bern, 3010, Bern, Switzerland.

Olgun Elicin (O)

Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, 3010, Bern, Switzerland. olgun.elicin@insel.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH